Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for neuroinflammation and immunology (NI&I) indications with significant unmet need. Its lead programs are PIPE-791 for chronic pain and PIPE-307 for depression, with PIPE-307 being advanced in collaboration with Johnson & Johnson.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaLead therapeutic programs in development, including PIPE-791 and PIPE-307.
License and milestone economics tied to the J&J agreement for PIPE-307.
Internal discovery and preclinical work supporting future NI&I indications.
Asiakkaat
Contineum does not sell approved commercial products today; its current counterparties are primarily development partners, regulators, clinical trial sites, CROs, CMOs, and investors funding the pipeline. If approved in the future, its end customers would be patients treated for chronic pain, depression, and other NI&I conditions, with reimbursement decisions influenced by payors.
Johnson & Johnson funds and supports PIPE-307 development under the license agreement.
CROs, investigators, laboratories, and CMOs that execute trials and manufacture clinical supply.
FDA and comparable agencies that review safety, efficacy, and manufacturing readiness.
Patients with chronic pain or depression and the insurers that would reimburse approved therapies.
Strategia
Contineum’s strategy is to advance a focused pipeline of selective small molecules for NI&I diseases, using PIPE-791 and PIPE-307 as the core value drivers. The company is prioritizing clinical execution, regulatory progress, intellectual property protection, and external financing while leveraging the J&J collaboration to reduce development burden on PIPE-307.
Pipeline value depends on successful clinical data and regulatory milestones.
The company expects operating expenses to rise materially as trials expand.
Patent protection and operational readiness are essential before commercialization.
Maantiede
Contineum is headquartered in San Diego, California, and its operating footprint is centered in the United States. The company disclosed office and laboratory leases in San Diego, while its future commercial exposure would likely broaden only if its drug candidates are approved and launched.
Riskit
Contineum is highly dependent on two early-stage drug candidates, so clinical setbacks, safety issues, or regulatory delays could materially impair the business. Like other biopharma developers, it also faces financing risk, manufacturing and supply-chain risk, and payer/competitive pressure if products are ever approved.
- Pipeline concentrationVaikutus: KriittinenTodennäköisyys: Korkea
The company is heavily dependent on two early-stage assets, so any failure would materially reduce prospects.
Kohdistuu: PIPE-791 and PIPE-307
- Clinical and regulatory failureVaikutus: KorkeaTodennäköisyys: Korkea
Drug candidates may not demonstrate efficacy, safety, or approvability in trials.
Kohdistuu: Phase 1/2 and later-stage development
- Financing and dilutionVaikutus: KorkeaTodennäköisyys: Korkea
Operating losses and trial costs require ongoing capital raises before any product revenue exists.
Kohdistuu - Manufacturing and supply chainVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Clinical and future commercial supply depends on qualified third-party manufacturers and compliant facilities.
Kohdistuu - Competitive and reimbursement pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Approved therapies for pain and depression include generics and established branded drugs, limiting pricing power.
Kohdistuu: Future commercialization
Kirjanpito
Harkinnanvaraiset erätRevenue is tied to the J&J agreement and is recognized as performance obligations are satisfied.
Vaikutus: Milestone timing can create lumpy quarterly revenue.
Clinical, CRO, and manufacturing costs are estimated and accrued before invoices are finalized.
Vaikutus: Changes in trial activity can shift expense recognition between periods.
Employee and director equity awards are valued using judgmental assumptions.
Vaikutus: Can materially affect operating expense and reported losses.
The company disclosed estimates for common stock and convertible preferred stock valuation.
Vaikutus: Important around financing events and equity issuances.
Office and laboratory leases in San Diego create fixed obligations under lease accounting.
Vaikutus: Affects balance sheet liabilities and operating cash commitments.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
CNS Pharmaceuticals, Inc.
CNSP · Pharmaceutical Preparations
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
Equillium, Inc.
EQ · Pharmaceutical Preparations
Cullinan Therapeutics, Inc.
CGEM · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026